Published in J Clin Invest on April 01, 2000
The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother (2009) 1.06
Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer (2011) 0.85
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate (2002) 0.79
Delivery strategies for novel vaccine formulations. World J Virol (2012) 0.76
Ectopic expression of vaccinia virus E3 and K3 cannot rescue ectromelia virus replication in rabbit RK13 cells. PLoS One (2015) 0.75
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene (1983) 3.94
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther (1999) 2.00
New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res (1990) 1.58
Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors. Virology (1992) 1.13
Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res (1994) 1.01
In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol (1996) 0.95
Strategies in the development of recombinant vaccines for colon cancer. Semin Oncol (1999) 0.84
Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 2.12
MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol (1997) 2.12
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther (1999) 2.00
Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science (1990) 1.79
The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol (1999) 1.72
Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res (1999) 1.58
The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med (2001) 1.53
Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice. Immunity (2000) 1.47
De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A (1995) 1.43
Clinical and US findings in prostate cancer: patients with normal prostate-specific antigen levels. Radiology (1993) 1.42
Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J Immunol (1998) 1.40
Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames. J Exp Med (1996) 1.39
Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity. J Immunol (2000) 1.23
Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J Immunol (1997) 1.20
Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res (1993) 1.18
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol (1997) 1.16
Natural cytotoxic cells against solid tumors in mice: blocking of cytotoxicity by D-mannose. Proc Natl Acad Sci U S A (1980) 1.16
The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol (2001) 1.14
Ia-dependent interleukin 2 production in syngeneic cellular interactions. J Immunol (1982) 1.13
Interleukin 10 production by human melanoma. Clin Cancer Res (1996) 1.12
Natural cytotoxic cells against solid tumors in mice. III. A comparison of effector cell antigenic phenotype and target cell recognition structures with those of NK cells. J Immunol (1981) 1.05
Interleukin 2, production in the syngeneic mixed lymphocyte reaction. Eur J Immunol (1981) 1.04
Initiation codon scanthrough versus termination codon readthrough demonstrates strong potential for major histocompatibility complex class I-restricted cryptic epitope expression. J Exp Med (1997) 1.03
The activity of natural cytotoxic cells is augmented by interleukin 2 and interleukin 3. J Exp Med (1983) 1.02
Regulation of class I-restricted epitope processing by local or distal flanking sequence. J Immunol (1997) 1.01
Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res (1994) 1.01
Specific neonatally induced tolerance to Mls locus determinants. J Immunol (1985) 1.00
Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. J Urol (1997) 1.00
Role of receptor-binding activity of the viral hemagglutinin molecule in the presentation of influenza virus antigens to helper T cells. J Virol (1987) 1.00
Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clin Pharmacol Ther (2007) 1.00
Quantitative analysis of adenovirus-specific CD4+ T-cell responses from healthy adults. Viral Immunol (2001) 0.99
Lyt 1 cells respond to Ia-bearing macrophages in the murine syngeneic mixed lymphocyte reaction. Eur J Immunol (1980) 0.99
Clinically occult Leydig cell tumor presenting with gynecomastia. J Urol (1989) 0.98
In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol (1996) 0.95
Prazosin and phentolamine: comparative cardiovascular and autonomic profiles. Clin Exp Hypertens (1978) 0.91
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol (1995) 0.90
Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol (2001) 0.90
Murine non-lymphoid tumors are lysed by a combination of NK and NC cells. Int J Cancer (1983) 0.89
Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol (2000) 0.88
Natural cytotoxic cells against solid tumors in mice. IV. Natural cytotoxic (NC) cells are not activated natural killer (NK) cells. Int J Cancer (1982) 0.86
Antigen processing of two H2-IEd-restricted epitopes is differentially influenced by the structural changes in a viral glycoprotein. J Immunol (1998) 0.84
Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology (1995) 0.84
Murine transporter associated with antigen presentation (TAP) preferences influence class I-restricted T cell responses. J Exp Med (1997) 0.83
Identification of overlapping class I and class II H-2d-restricted T cell determinants of influenza virus N1 neuraminidase that require infectious virus for presentation. Virology (1994) 0.82
L3T4+, B2A2+ thymocytes from infant mice produce IL 2 after interaction with accessory cells expressing self class II antigens. J Immunol (1986) 0.81
Allogeneic radiation chimeras respond to TNP-modified donor and host targets. J Immunol (1980) 0.80
Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother (1994) 0.80
Arteriosclerosis: is stress-induced immune suppression a risk factor? Science (1977) 0.79
Processing and presentation of antigens to class I restricted T lymphocytes. Year Immunol (1990) 0.79
Natural cytotoxic (NC) activity: a multi-lineage system regulated by IL-2. Immunol Res (1986) 0.79
Neutralizing anti-IL-10 antibody upregulates the induction and elicitation of contact hypersensitivity. J Interferon Cytokine Res (1997) 0.78
Physarum myosin light chain binds calcium. Cell Motil (1980) 0.78
Natural cytotoxic cells against solid tumors in mice: a comparison with natural killer cells. Fed Proc (1981) 0.78
Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice. J Urol (1996) 0.78
Characterization of cytotoxic cells generated from bone marrow culture. Cell Immunol (1986) 0.77
The generation of culture activated killer cells (AK) is interleukin-2-dependent and requires self-Ia recognition. Int J Cancer (1985) 0.77
Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys (2001) 0.77
Ultrasound-guided four quadrant biopsy of the prostate: efficacy in the diagnosis of isoechoic cancer. Clin Radiol (1994) 0.77
Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study. Cancer Biother (1993) 0.77
Virus entry and antigen biosynthesis in the processing and presentation of class-II MHC-restricted T-cell determinants of influenza virus. Immunol Res (1990) 0.76
Re: Interleukin-2 in T1 papillary bladder carcinoma: regression of the marker lesion in 8 of 10 patients. J Urol (1998) 0.76
Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clin Immunol Immunopathol (1997) 0.75
Use of dendritic cells to immunize against cancers overexpressing p53. Clin Cancer Res (2001) 0.75
Host age and H-2 tolerance in chimeric mice: mixed lymphocyte reactivity, cell-mediated lympholysis and responses to hapten-modified self. Mech Ageing Dev (1980) 0.75
l-Bunolol and propranolol: oral and intravenous beta-adrenoceptor blocking activity in rats compared to dogs and humans. J Pharm Sci (1978) 0.75
Natural killer and other effector cells. Symp Fundam Cancer Res (1986) 0.75
Characterization of IL-2-dependent cytotoxic T-cell clones. III. Inhibition of killing activity by monosaccharides. Cell Immunol (1983) 0.75
Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. Urology (1998) 0.75
Prostate imaging may not be necessary in nonpalpable carcinoma of the prostate. Urology (1997) 0.75
Total incontinence secondary to sphincter destruction after prostate cryotherapy for recurrent prostatic carcinoma. Int J Urol (1996) 0.75
A new occluding device for producing Goldblatt hypertension in the rat. J Pharm Pharmacol (1975) 0.75
Antihypertensives. 1. Syntheses of thiazino-, thiazepino-, and thiazoninoethylguanidines. J Med Chem (1974) 0.75
Cellular vaccine therapies for cancer. Cancer Treat Res (1998) 0.75
Natural cytotoxic activity in murine and human systems. A review. Year Immunol (1986) 0.75
Soluble Fc gamma RIII (CD16) and immunoglobulin G levels in seminal plasma of men with immunological infertility. J Androl (1993) 0.75
Susceptibility to lysis by natural killer and natural cytotoxic cells is independent of the mitotic stage of the target cell cycle. Cell Immunol (1986) 0.75
Natural cell-mediated cytotoxicity against tumors in mice: an heterogeneous system. Transplant Proc (1981) 0.75
Ia dependent lymphokine production in the syngeneic mixed lymphocyte response. Behring Inst Mitt (1983) 0.75
Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters. Cancer Biother Radiopharm (1998) 0.75
Intravesical growth of murine bladder tumors assessed by transrectal ultrasound. J Urol (1993) 0.75
Natural cytotoxic (NC) cell activity in murine and human systems. Effector cells from multiple lineages with antitumor activity. Concepts Immunopathol (1987) 0.75
B-Myb overexpression results in activation and increased Fas/Fas ligand-mediated cytotoxicity of T and NK cells. J Immunol (2001) 0.75
Ia antigen-stimulated proliferation and IL-2 production in the syngeneic mixed lymphocyte reaction. Transplant Proc (1981) 0.75
Use of vaccinia virus expression vectors to investigate antigen processing and presentation. Methods Mol Biol (2001) 0.75
Gene therapy for human cancer: an essay for clinicians. Semin Oncol (1996) 0.75
Radiation Therapy Oncology Group. Research Plan 2002-2006. Surgical Oncology Committee. Int J Radiat Oncol Biol Phys (2001) 0.75